This Is What Whales Are Betting On CRISPR Therapeutics

Someone with a lot of money to spend has taken a bearish stance on CRISPR Therapeutics CRSP.

And retail traders should know.

We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with CRSP, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 13 options trades for CRISPR Therapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 38% bullish and 61%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $33,600, and 12, calls, for a total amount of $616,363..

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $80.0 for CRISPR Therapeutics over the last 3 months.

Volume & Open Interest Development

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 303.8 with a total volume of 959.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $40.0 to $80.0 over the last 30 days.

CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Where Is CRISPR Therapeutics Standing Right Now?

• With a volume of 3,359,528, the price of CRSP is up 7.1% at $67.92.
• RSI indicators hint that the underlying stock may be overbought.
• Next earnings are expected to be released in 89 days.

What The Experts Say On CRISPR Therapeutics:

• Cantor Fitzgerald downgraded its action to Overweight with a price target of $72
• JMP Securities downgraded its action to Market Outperform with a price target of $70
• Needham downgraded its action to Buy with a price target of $82
• Needham downgraded its action to Buy with a price target of $82
• RBC Capital downgraded its action to Sector Perform with a price target of $50

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.